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Abstract
Background: Transcription factor Snail1 has a central role in induction of epithelial-mesenchymal
transition (EMT). The aim of the present study was to elucidate the expression of Snail1 protein
during epithelial ovarian tumourigenesis and to study the association of Snail1 expression with
clinicopathological factors and prognosis.
Methods: Epithelial and stromal fibroblast-like fusiform cells of 14 normal ovarian samples, 21
benign, 24 borderline and 74 malignant epithelial ovarian tumours were studied for Snail1 protein
using immunohistochemistry.
Results: Nuclei of surface peritoneal cells of normal ovaries (n = 14) were regarded as negative
for Snail1. Nuclear expression of Snail1 protein in epithelial ovarian tumours was increased during
tumour progression from precursor lesions into carcinomas both in epithelial (p = 0.006) and
stromal cells (p = 0.007). Nuclei of benign tumours (n = 21) were negative for Snail1. In borderline
tumours (n = 24) occasional positive epithelial cells were found in 2 (8%) samples and in 3 (13%)
samples stromal cells were focally positive for Snail1. In carcinomas (n = 74) focal Snail1 staining in
epithelial cells was present in 17 (23%) tumours, and in stromal cells in 18 (24%) tumours. Nuclear
expression of Snail1 in epithelial or stromal cells was not associated with clinicopathological factors
or prognosis.
Conclusion:  Nuclear Snail1 expression seems to be related to tumour progression, and
expression in borderline tumours indicates a role for Snail1 in early epithelial ovarian tumour
development. Snail1 also appears to function more generally in tissue remodelling as positive
staining was demonstrated in stromal cells.
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Background
Ovarian cancer is among the most common cancers in
women worldwide and a common cause of cancer deaths
[1]. It consists of several histological types: serous, muci-
nous, clear cell and endometrioid adenocarcinomas
which all belong to epithelial tumours. Although the pre-
cursor lesion of epithelial ovarian cancer is still yet uni-
dentified, the two-pathway model of ovarian cancer
pathogenesis is gaining acceptance [2-4]. Type I tumours,
i.e. low-grade serous ovarian carcinoma and mucinous
ovarian cancers probably arise from benign adenomas
and borderline tumours, and clear cell and endometrioid
tumours may develop from endometriosis. Type II
tumours, i.e. high grade serous ovarian cancer with aggres-
sive phenotype is thought to arise directly from the surface
epithelium of the ovary or from inclusion cysts.
Ovarian surface epithelial cells can convert to mesenchy-
mal, fibroblast-like phenotype at least in vitro [5]. This epi-
thelial-mesenchymal transition (EMT) is a complex
cellular process during which cellular phenotype and
function is changed [6]. EMT occurs in normal physiolog-
ical processes during embryogenesis and wound healing.
It has also been recognised in different pathological proc-
esses, e.g. in fibrosis and carcinomas [6]. Our previous
results indicate that EMT occurs in epithelial ovarian car-
cinoma [7]. In addition to tumour invasion and metasta-
sis EMT has been connected to early steps of
carcinogenesis in epithelial malignancy [8,9].
Transcription factor Snail1 has been considered to have a
key role in the induction of EMT [10]. Snail1 is a repressor
of E-cadherin, an adherens junction protein maintaining
cell-cell adhesion in epithelium. Snail1 may also enhance
levels of other EMT inducing transcription factors such as
ZEB-1 and ZEB-2 [11]. Due to expression of Snail1 and
other EMT regulatory transcription factors epithelial cells
lose many of their epithelial characteristics and take on
the properties which are typical of mesenchymal cells.
Snail1 may produce changes in cell shape, migration and
invasion. It can regulate cell cycle progression and prevent
cell proliferation by attenuating cyclin D2 transcription
and increasing the expression of p21 [12]. Snail1 may also
prevent apoptosis by activating MAPK and PI3K survival
pathways [12].
Expression of Snail1 in epithelial cells of different malig-
nant tumours has been investigated in several studies with
dissimilar results [13]. Recently developed two mono-
clonal anti- Snail1 antibodies are well-characterised and
show clear nuclear staining of the protein in different
tumour types [11,14,15]. Using one of these antibodies,
Blechschmidt et al. [16] have detected nuclear staining of
Snail1 in 38% (18/48) of ovarian carcinomas and in 29%
(25/87) of endometrial cancers [17]. Snail1 may be
important in the pathogenesis of spindle cell carcinomas
of the head and neck as nuclear staining has been reported
in 63% (19/30) of cases [18]. However, lower nuclear
staining has been detected in adenocarcinomas of upper
gastrointestinal tract and other types of head and neck
squamous cell carcinomas [15,18,19]. In addition, Snail1
staining in cell cytoplasm and/or nucleus has been
observed in 16% (40/251) of laryngeal squamous cell car-
cinomas [20]. In ovarian cancer, Snail1 mRNA has been
detected more frequently than protein since 93% (38/41)
of primary tumours expressed mRNA [21]. Snail1 positive
stromal cells have previously been detected in many
adeno and squamous cell carcinomas [14-19,21]. How-
ever, there are no published data about Snail1 expression
in precursor ovarian lesions.
To elucidate more properly the role of Snail1 in human
epithelial ovarian tumour development we have analysed
Snail1 protein in epithelial and stromal compartments of
normal ovaries and in benign, borderline and malignant
ovarian tumours by immunohistochemistry. In addition,
to evaluate the prognostic value of Snail1 protein expres-
sion we have compared the results with known clinical
data of the patients.
Methods
Patients
Our ovarian material consisted of 14 normal ovarian sam-
ples, 21 benign and 24 borderline epithelial ovarian
tumours and 74 epithelial ovarian carcinomas (Table 1).
The samples were collected in Kuopio University Hospi-
tal, Finland, between 1999 and 2005. Staging of primary
tumours was based on standards of the International
Union Against Cancer (UICC) [22]. Histological type and
grade were evaluated according to the World Health
Organisation (WHO) [23]. Patients who died because of
any postoperative complications (deaths within one
month after the operation) were not included in the sur-
vival analysis. Median follow-up time for all patients was
38 months (range 2–76 months). The research was
approved by the ethical committee of Kuopio University
and Kuopio University Hospital.
Immunohistochemistry
Five-μm-thick paraffin-embedded tissue sections of all
ovarian samples were stained immunohistochemically.
Shortly, after deparaffinisation and rehydration, the sec-
tions were heated in a microwave oven for 2 × 5 min in
Tris-EDTA buffer (pH 9.0), incubated in a Tris-EDTA
buffer for 20 min and washed twice for 5 min in phos-
phate buffered saline (PBS). Hydrogen peroxide (5%, 5
min) was used to block endogenous peroxidase, followed
by washing with water 2 × 5 min and with PBS for 2 × 5
min. Non-specific binding was blocked with 1,5% normal
serum in PBS for 35 min at room temperature. The sec-BMC Cancer 2009, 9:289 http://www.biomedcentral.com/1471-2407/9/289
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tions were incubated over night at 4°C with the mouse
monoclonal anti – Snail1 antibody (1:1000 dilution)
[11,14]. Negative control was incubated with 1% bovine
serum albumin in PBS. Next, the slides were washed with
PBS for 2 × 5 min and incubated with the biotinylated sec-
ondary antibody (ABC Vectastain Elite Kit, Vector Labora-
tories, Burlingame, CA, USA) for 45 min at room
temperature. After this, the slides were washed with PBS
for 2 × 5 min, incubated for 50 min in preformed avidin-
biotinylated peroxidase complex (ABC Vectastain Elite
Kit, Vector Laboratories, Burlingame, CA, USA) and
washed with PBS for 2 × 5 min. The colour was developed
with diaminobenzidine tetrahydrocloride (DAP) (Sigma,
St. Louis, MO, USA). The slides were counterstained with
Mayer's haematoxylin, washed, dehydrated, cleared and
mounted with Depex (BDH, Poole, UK).
Evaluation of the stainings
Snail1 expression in all samples was analysed by two
main observers (HT, LK) unaware of the clinical data and
three senior pathologists (YS, V-MK, RS) evaluated a sub-
set of the samples. The slides were first overviewed to find
five hot spot regions (areas with the maximum number of
positive cells per microscopic field) in the tissue studied.
Stained epithelial/stromal cell nuclei in these hot spot
regions were counted using 40 × objective [24]. For posi-
Table 1: Clinicopathological characteristics of the patients
Variable Normal Benign Borderline Carcinoma
Total 14 (100) 21 (100) 24 (100) 74 (100)
Median age at diagnosis, yearsa 59 [41–88]
Histologic subtype
Serous 10 (48)b 12 (50)b 41 (56)
Mucinous 10 (48)b 12 (50)b 7 (9)
Endometrioid 17 (23)
Clear cell 7 (9)
Other 1 (4)c 2 (3)d
Histological grade
1 9 (12)
2 32 (43)
3 33 (45)
Stage
I 12 (16)
II 8 (11)
III 36 (49)
IV 18 (24)
Primary residual tumour
None 30 (40)
≤ 1 cm 11 (15)
> 1 cm 33 (45)
Chemotherapy response
No data 6 (8)
Complete response 52 (70)
Partial response 2 (3)
Stable disease 1 (1)
Progressive disease 7 (10)
No chemotherapy 6 (8)
Tumour recurrence
No recurrence 20 (27)
Recurrence 31 (42)
No data 23 (31)
Patient status
Dead, ovarian cancer 30 (41)
Alive 40 (54)
Unknown 4 (5)
Median follow-up time, months 38 [2–76]
Values are n (%) unless stated otherwise.
aValues in square brackets indicate range.
bCystadenomas
cBrenner tumour
dInclude two adenocarcinomas not otherwise specified.BMC Cancer 2009, 9:289 http://www.biomedcentral.com/1471-2407/9/289
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tive nuclear staining in stromal compartment of the
tumours only fibroblast-like fusiform cells were included.
The division of samples to negative or positive as regards
to nuclear staining was assessed according to mean value.
Among epithelial tumour cells the mean was 3 nuclei
(range 0 – 49 nuclei) and among carcinoma associated
stromal cells the mean was 4 nuclei (0 – 79 nuclei). Cyto-
plasmic staining of Snail1 in epithelium was graded as
negative, when < 5% and positive, when ≥ 5% of the nor-
mal/tumour cells were positive for Snail1 [17].
Statistical analysis
The statistical analyses were performed using SPSS 14.0
software (SPSS Inc., Chicago, IL, USA) except for testing
trend. Mann-Whitney test was used to examine the rela-
tionship between continuous variables. A chi-squared test
was used in analysing frequency tables. Interobserver
agreement for the positivity of the stainings was evaluated
by Spearman statistics. Univariate survival analyses were
evaluated using the Kaplan-Meier method. The statistical
differences between the curves were analysed using the
log-rank test. Multivariate survival analysis was calculated
using Cox's proportional hazards model. Disease related
survival was defined as the time between the date of sur-
gery and the date of death due to ovarian cancer. Recur-
rence free survival was defined by the time interval
between the date of surgery and the date of recurrence.
Trends were examined with chi-squared test for trend in
proportions using R version 2.7.2 (The R Foundation for
Statistical Computing).
Results
In normal ovaries (n = 14) surface peritoneal cell nuclei
were regarded as negative for Snail1 (Figure 1a). There
were no signs of the protein in stroma either.
In tumours an increased nuclear Snail1 content was asso-
ciated with increasing tumour malignancy both in epithe-
lial (p = 0.006) and stromal compartments (p = 0.007)
(Table 2). In benign tumours (n = 21) all epithelial and
stromal cell nuclei were negative. In borderline tumours (n
= 24) nuclear positive epithelial cells were observed
focally in 2 (8%) samples (Figure 1b) and stromal cells
were focally positive in 3 (13%) samples.
In carcinomas (n = 74) focal nuclear Snail1 immunoreac-
tivity in epithelial cells was present in 17 (23%) samples
(Figure 1c). In carcinoma-associated stromal cells the
staining was focal and observed in 18 (24%) cases (Figure
1d). A good agreement was found between the evalua-
tions in staining positivity between the observers (Spear-
man's correlation coefficient 0.599). No association was
found between nuclear Snail1 expression in epithelium or
stroma or between Snail1 expression and clinicopatholog-
ical factors including histological subtype, grade, stage,
primary residual tumour, chemotherapy response and
tumour recurrence. Further, nuclear Snail1 expression was
not related to overall survival or recurrence free survival.
Nuclear staining of Snail1 protein in the subset of
endothelial cells was demonstrated in normal ovaries as
well as in benign, borderline and malignant tumours (Fig-
ure 1e).
In addition to nuclear staining also cytoplasmic Snail1
immunoreactivity was evaluated in epithelial cells of nor-
mal ovary and different tumour types. In epithelial inclu-
sions of normal ovaries positive cytoplasmic staining was
observed in 57% (8/14) of the samples. Decreased cyto-
plasmic expression of Snail1 in epithelial cells of the
tumours was related to increasing tumour malignancy (p
< 0.001). While 90% (19/21) of the benign tumours
showed positive cytoplasmic staining 83% (20/24) of the
borderline tumours and only 43% (32/74) of the carcino-
mas were positive (Figure 1f). Cytoplasmic expression in
carcinoma cells did not associate with any of the analysed
clinicopathological factors or nuclear staining in malig-
nant cells.
Discussion
Several lines of evidence show that EMT has a central role
in invasion and metastasis of different types of tumours
facilitating conversion of polarized, epithelial phenotype
to motile fibroblastoid or mesenchymal phenotype [6].
Recently EMT markers have also been associated with
early steps of tumourigenesis [8,9]. The aim of this study
was to elucidate the role of transcription factor Snail1, an
inducer of EMT, in the development of epithelial ovarian
tumours.
According to our results nuclear expression of Snail1 pro-
tein seems to be a feature of tumour progression in epithe-
lial ovarian tumourigenesis. Increased Snail1 expression
was associated with increasing tumour malignancy both
in epithelial compartment (p = 0.006) and in stromal
compartment (p = 0.007). Our result is in concordance
with previous studies indicating Snail1 as a regulator of
EMT as well as literature describing it as an inducer of
invasive phenotype [10]. However, Snail1 protein may
have additional roles in different types of tumours.
Nuclei of all benign tumours were negative for Snail1. In
line with our results one report presented negative Snail1
expression in mouse intestinal adenomas, and another in
human hyperplastic oral mucosa [19,25]. However, dys-
plastic oral mucosa has been reported to show single dis-
tributed Snail1 positive cells [19]. We found similarly
focally positive nuclear Snail1 protein staining in border-
line ovarian tumours. Snail1 expression in precursor
lesions may suggest a role for the protein in early ovarian
tumourigenesis before invasion or metastasis. Its expres-BMC Cancer 2009, 9:289 http://www.biomedcentral.com/1471-2407/9/289
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sion in borderline tumours might be related to other
known functions of Snail1. Indeed, members of Snail1
family can also act as more general regulators of cell adhe-
sion and movement in EMT-related or EMT-independent
manner [26]. In cancer Snail1 has been described to act
primarily as a survival factor and an inducer of cell move-
ment rather than as an inducer of EMT [27]. Peinado et al.
have proposed that Snail1 could be implicated in the ini-
tial migratory phenotype of primary tumours and consid-
ered it as an early marker of EMT, at least in ovarian
tumours [10].
In the vast majority of the Snail1 positive ovarian carcino-
mas the nuclear protein was stained focally at rather low
levels in the tumour epithelium and stroma. Nuclear con-
tent of Snail1 in epithelium or stroma in our material was
not related to clinicopathological features, like tumour
grade or stage of disease, nor had it prognostic signifi-
cance. Relatively small material and short follow-up time
of the patients could effect on this. However, nuclear
staining was detected in borderline tumours suggesting
that Snail1 might be an early factor in ovarian tumour
development. Nevertheless, supporting our findings
rather similar results have been reported [16]. In another
ovarian cancer study using the material of 48 primary
tumours nuclear Snail1 staining in epithelial cells in 38%
of the primary tumours did not associate with any clinico-
pathological factors or overall survival [16].
Stromal cells are essential in tumourigenesis [28]. Pres-
ence of Snail1 positive stromal cells has previously been
detected in various adeno and squamous cell carcinomas
[14-19,21]. In our study, similar staining of Snail1 protein
was observed both in stromal fibroblast-like fusiform cells
and epithelial cells of ovarian carcinomas. Thus, a tumour
may create its own stroma originating from malignant
epithelium to facilitate tumour growth [29] and Snail1
could be a marker of these cells that have just undergone
EMT [14]. Indeed, in vitro Snail1-transfected (squamous)
carcinoma cells show complete EMT phenotype with
fibroblastic characteristics [11]. However, in the present
study expression of Snail1 in stromal cells was also
detected in borderline tumours that do not have histolog-
ical evidence of stromal invasion indicating that Snail1
may have also other functions in stromal fibroblast-like
fusiform cells [27]. Snail1 has also been identified as a
regulator of terminally differentiated mesenchymal cells
[30], and further, during tumourigenesis, Snail1 expres-
sion in stromal cells may indicate interactions of fibrob-
lasts with dedifferentiated tumour cells [19]. Snail1-
induced EMT has been proposed also to accelerate cancer
metastasis by enhancing invasion and by inducting
immunosuppression [31]. Altogether, Snail1 expression
in the stroma of borderline tumours may indicate impor-
tance of the microenvironment already in premalignant
tumours and supports the role of tissue remodelling effect
of Snail1.
In tumours, endothelial to mesenchymal transition
(EndMT) is an important source of cancer-associated
fibroblasts [32]. Some of the endothelial cell nuclei in this
ovarian carcinoma study were positive for Snail1. Snail1
staining in a subset of endothelial cells has been reported
in adeno and squamous cell carcinomas [15,18,19]. How-
ever, we found positive endothelial cells also in benign
and borderline tumours as well as in normal ovaries. A
previous report has demonstrated that angiogenic vessels
can undergo EndMT [32]. Kokudo et al. showed that
mouse endothelial cells can differentiate into mural cells,
such as pericytes and/or smooth muscle cells, and that
Staining of Snail1 protein in ovarian samples Figure 1
Staining of Snail1 protein in ovarian samples. a) A nor-
mal ovary with negative surface peritoneal cell nuclei (× 200). 
b) A serous borderline tumour with nuclear staining in some 
epithelial cells (arrow). Tumour stroma is indicated by aster-
isk. (× 200). c) A clear cell carcinoma with positive epithelial 
cell nuclei (arrows) (× 100). Insert (× 400). d) An endometri-
oid carcinoma with positive nuclear staining both in epithelial 
and stromal fibroblast-like fusiform cells (arrows) (× 200). 
Insert (× 400). e) A benign serous cystadenoma with nuclear 
staining in a subset of endothelial cells (arrows) (× 200). f) A 
benign serous cystadenoma with focal cytoplasmic staining in 
epithelial cells (× 200).BMC Cancer 2009, 9:289 http://www.biomedcentral.com/1471-2407/9/289
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Snail1 is associated with the process [33]. Also in normal
human ovaries new blood vessel formation and subse-
quent regression occurs in each hormonal cycle [34].
Besides nuclear protein content we have also analysed
cytoplasmic staining of Snail1 protein in epithelial cells.
Opposite to nuclear immunoreactivity, we observed
decreased cytoplasmic expression of Snail1 in epithelium
that was significantly associated with increasing tumour
malignancy (p < 0.001). Transcription factor Snail1 activ-
ity is controlled by subcellular location and cytoplasmic
form of the protein is not considered active [10]. Keeping
this in mind, cytoplasmic staining may point to post-tran-
scriptional regulation of the protein in epithelial ovarian
carcinomas [10,21] and in pre-malignant tumours, as
shown in the present material.
Conclusion
Nuclear expression of Snail1 protein in epithelial ovarian
tumours was increased during tumour progression from
precursor lesions into carcinomas. Snail1 expression
detected in borderline tumours suggests a role for Snail1
also in early ovarian tumourigenesis preceding tumour
invasion and metastasis. In addition, stromal positivity of
Snail1 in borderline and malignant tumours underlines
the importance of tumour microenvironment during
development and progression of ovarian tumours.
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